PD-1 and PD-L2 expression predict relapse risk and poor survival in patients with stage III colorectal cancer
Yükleniyor...
Dosyalar
Tarih
2021
Dergi Başlığı
Dergi ISSN
Cilt Başlığı
Yayıncı
Springer Science and Business Media B.V.
Erişim Hakkı
info:eu-repo/semantics/closedAccess
Özet
Background: Immune responses have long been an area of interest in cancer research. In this study, the effects of programmed cell death-1 (PD-1) and its ligand (PD-L2) on the prognosis of colorectal cancer (CRC) were investigated. Methods: Primary tumour specimens of stage III CRC patients operated between 2002 and 2013 were assessed for PD-1 and PD-L2 expression and various clinicopathological and prognostic factors. Results: We observed a significant relationship between poor prognostic factors and PD-1/PD-L2 expression. These biomarkers were also found to serve as independent risk factors for LIR and MSI. In univariate analysis, relapse-free survival (RFS) and overall survival (OS) rates were found to be poor in PD-1 and PD-L2 positive patients. In multivariate analysis, these biomarkers were found to serve as independent poor prognostic factors for RFS and OS. Conclusions: Our data indicate that PD-1 and PD-L2 may serve as independent prognostic survival parameters for CRC patients and may be employed for the design of targeted therapies. © 2021, Springer Nature Switzerland AG.
Açıklama
Anahtar Kelimeler
Colorectal cancer, PD-1, PDL-2, Prognostic biomarkers, Stage III, mismatch repair protein, programmed death 1 ligand 1, programmed death 1 ligand 2, adult, aged, Article, cancer patient, cancer recurrence, cancer risk, cancer staging, cancer survival, clinical assessment, colorectal cancer, controlled study, female, follow up, histopathology, human, human tissue, immune response, inflammation, major clinical study, male, microsatellite instability, microscopy, overall survival, primary tumor, priority journal, protein expression, recurrence free survival, relapse, risk assessment, risk factor, surgical margin, tumor microenvironment
Kaynak
Cellular Oncology
WoS Q Değeri
Q1
Scopus Q Değeri
Q1
Cilt
44
Sayı
2
